CD300LF
CMRF35-like molecule 1
Also known as: CD300f, CLM1, CLM1_HUMAN, IGSF13, IREM1, NKIR
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8TDQ1
- Gene
- CD300LF
- Ensembl
- ENSG00000186074
- Chromosome
- 17
- Canonical length
- 290 aa
- Protein class
- CD markers, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a member of the CD300 protein family. Members of this family are cell surface glycoproteins with a single IgV-like extracellular domain, and are involved in the regulation of immune response. The encoded protein is an inhibitory receptor. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]
Canonical amino-acid sequenceUniProt
290 residues, UniProt reviewed canonical sequence.
>Q8TDQ1|CD300LF
1 MPLLTLYLLL FWLSGYSIVT QITGPTTVNG LERGSLTVQC VYRSGWETYL KWWCRGAIWR
61 DCKILVKTSG SEQEVKRDRV SIKDNQKNRT FTVTMEDLMK TDADTYWCGI EKTGNDLGVT
121 VQVTIDPAPV TQEETSSSPT LTGHHLDNRH KLLKLSVLLP LIFTILLLLL VAASLLAWRM
181 MKYQQKAAGM SPEQVLQPLE GDLCYADLTL QLAGTSPQKA TTKLSSAQVD QVEVEYVTMA
241 SLPKEDISYA SLTLGAEDQE PTYCNMGHLS SHLPGRGPEE PTEYSTISRPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD300LF can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.52
- Highest tissue expression
- 29 nTPM
Expression across tissuesHPA
Tissue
- spleen: 29 nTPM
- bone marrow: 26 nTPM
- lung: 17 nTPM
- appendix: 13 nTPM
- lymph node: 8.3 nTPM
- tonsil: 5.1 nTPM
Single-cell type
- tuft cells: 173 nCPM
- neutrophils: 95 nCPM
- monocytes: 49 nCPM
- monocyte progenitors: 43 nCPM
- neutrophil progenitors: 36 nCPM
- kupffer cells: 30 nCPM
Immune cell
- eosinophil: 235 nTPM
- non-classical monocyte: 194 nTPM
- intermediate monocyte: 165 nTPM
- classical monocyte: 96 nTPM
- neutrophil: 75 nTPM
- myeloid DC: 64 nTPM
Brain region
- cerebellum: 13 nTPM
- white matter: 6.9 nTPM
- thalamus: 6.4 nTPM
- medulla oblongata: 5.5 nTPM
- pons: 5.2 nTPM
- spinal cord: 3.8 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.44
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.36
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- immune response-activating signaling pathway
- interleukin-13-mediated signaling pathway
- negative regulation of apoptotic cell clearance
- negative regulation of mast cell activation
- negative regulation of MyD88-dependent toll-like receptor signaling pathway
- positive regulation of apoptotic cell clearance
- positive regulation of interleukin-4-mediated signaling pathway
- TRIF-dependent toll-like receptor signaling pathway
Molecular functions
- ceramide binding
- identical protein binding
- interleukin-4 receptor binding
- phosphatidylserine binding
- transmembrane signaling receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CD300LF in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD300LF as an antibody target. Whether an autoantibody or antibody against CD300LF could matter depends on whether native CD300LF is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD300LF is annotated at the cell surface, where native CD300LF is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD300LF as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...